Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases commands the majority of treatment focus due to its predominance.

Currently, the primary treatment revolves around checkpoint inhibitors (CPIs) and tyrosine kinase inhibitors (TKIs). However, prognosis takes a downturn when patients progress on these drug classes, highlighting the pressing need for innovative solutions.

At AACR 2024, findings from a Phase 1 (COBALT-RCC) trial investigating allogeneic CAR T cell treatment (CTX130) in patients with advanced clear cell renal cell carcinoma are encouraging.CTX130 uses T cells from healthy donors edited to target CD70 and to disrupt the TRAC and β2M genes, which should reduce graft vs. host disease and donor rejection.

Long-term follow-up and translational data from the COBALT-RCC study underscore the promising antitumor activity and remarkable safety profile of CTX130 in advanced ccRCC patients. Impressively, 81% of patients experienced clinical benefit CR/partial response/SD), with 75% exhibiting stable disease and one individual achieving a durable complete response lasting over three years—a landmark achievement in allogeneic, off-the-shelf CAR T cell therapy for refractory solid tumors.

Building upon these findings, CRISPR Therapeutics has developed CTX131, an improved version of CTX130. Currently, patients are being enrolled in a Phase I/II clinical trial (NCT05795595) to evaluate the potential of this novel therapy in adult patients with relapsed/refractory solid tumors.

For more information, refer DelveInsight’s report:
Advanced Renal Cell Carcinoma (RCC) – Market Insight, Epidemiology And Market Forecast – 2032